Clearside Biomedical's XIPERE was officially launched by partner Bausch + Lomb in Q1. See why I think a gene therapy partnership is likely upcoming for CLSD.
Bausch Health Companies' (BHC) charts continue to look out of focus, writes technical analyst Bruce Kamich, who believes the technical signals of the diversified health care company still don't inspire confidence to establish long positions in its stock at this time..BHC
Bausch + Lomb is returning to the public markets in an IPO expected to rank among the biggest in healthcare. Speaking at the annual J.P. Morgan Healthcare Conference, Bausch Health Companies CEO Joe Papa discussed the plans to spin off both the iconic eye products business as well as the skin products business, leaving three independent and publicly traded companies.